Results 191 to 200 of about 54,960 (249)

Tumor sink effect on melanin-ligand [¹³¹I]ICF01012 in melanoma and its implications for targeted radionuclide therapy. [PDF]

EJNMMI Res
Jouberton E, Besse S, Billoux T, Auzeloux P, Schmitt S, Chezal JM, Sas N, Noirault L, Auriol M, Levesque S, Delmas M, Chaussin B, Chautard E, Miot-Noirault E, Rouanet J, Cachin F.   +15 more
europepmc   +1 more source

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. [PDF]

Pharmaceuticals (Basel)
Leupe H, Cauwenbergh M, Cleeren F, Dekervel J, Verslype C, Deroose CM.   +5 more
europepmc   +1 more source

Targeted Radionuclide Therapy Activates Prodrugs for Treating Metastasis. [PDF]

ACS Cent Sci
Guo Z, Wang X, Han Y, Shen S, Tian P, Hu Y, Ding Z, Fu Q, Liu Z.   +8 more
europepmc   +1 more source

Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience. [PDF]

Endocr Oncol
Chow W, Wen I, Mok C, Huang K, Stevenson W, Roach PJ, Bailey DL, Diakos CI, Clarke SJ, Pavlakis N, Chan DL.   +10 more
europepmc   +1 more source

Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy. [PDF]

Med Phys
Terro A, Perret S, Dumouchel A, Tonnelet D, Edet-Sanson A, Vera P, Decazes P, Dieudonné A.   +7 more
europepmc   +1 more source

Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years. [PDF]

Theranostics
Zhang J, Mensel B, Baum RP.
europepmc   +1 more source

Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade. [PDF]

Front Nucl Med
Haugh KN, Sanwick AM, Chaple IF.
europepmc   +1 more source

IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. [PDF]

Int J Mol Sci
Vuleta Nedic K, Gajovic N, Jovanovic I, Jurisevic M, Jovanovic M, Jakovljević S, Popovic B, Djordjevic J, Ignjatovic V, Vukomanovic V.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Radionuclide Therapy

Clinical Oncology, 1999
Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment.
R B, Buchanan, V J, Lewington
exaly   +7 more sources